

Joseph A Lasky

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6676131/publications.pdf>

Version: 2024-02-01

55
papers

8,660
citations

236612

25
h-index

161609

54
g-index

59
all docs

59
docs citations

59
times ranked

9184
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of Circulating Proteins with Death or Lung Transplant in Patients with Idiopathic Pulmonary Fibrosis in the IPF-PRO Registry Cohort. <i>Lung</i> , 2022, 200, 11-18.	1.4	2
2	A New Piece to Help Solve the Interstitial Lung Disease Diagnostic Puzzle. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 158-160.	2.5	2
3	Design and Rationale of a Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study Evaluating Dociparstat in Acute Lung Injury Associated with Severe COVID-19. <i>Advances in Therapy</i> , 2021, 38, 782-791.	1.3	12
4	Hypercoagulability in ICU Patients With Coronavirus Disease 2019 With Respiratory Failure Results in Increased Prevalence of Venous Thromboembolic Disease. <i>Chest</i> , 2021, 159, 1208-1211.	0.4	0
5	Delphi Consensus Recommendations on Management of Dosing, Adverse Events, and Comorbidities in the Treatment of Idiopathic Pulmonary Fibrosis with Nintedanib. <i>Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine</i> , 2021, 15, 117954842110060.	0.5	7
6	Update in Interstitial Lung Disease 2020. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 1343-1352.	2.5	21
7	Inhibition of HDAC6 Attenuates Tumor Growth of Non-Small Cell Lung Cancer. <i>Translational Oncology</i> , 2020, 13, 135-145.	1.7	24
8	Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Global Pharmacovigilance Data. <i>Advances in Therapy</i> , 2020, 37, 4209-4219.	1.3	21
9	BMI is Associated with Coronavirus Disease 2019 Intensive Care Unit Admission in African Americans. <i>Obesity</i> , 2020, 28, 1798-1801.	1.5	24
10	Circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with idiopathic pulmonary fibrosis in the multicenter IPF-PRO Registry cohort. <i>BMC Pulmonary Medicine</i> , 2020, 20, 64.	0.8	59
11	Using Bronchoscopic Lung Cryobiopsy and a Genomic Classifier in the Multidisciplinary Diagnosis of Diffuse Interstitial Lung Diseases. <i>Chest</i> , 2020, 158, 2015-2025.	0.4	21
12	Assessment of viral RNA in idiopathic pulmonary fibrosis using RNA-seq. <i>BMC Pulmonary Medicine</i> , 2020, 20, 81.	0.8	12
13	Pharmacotherapy and adjunctive treatment for idiopathic pulmonary fibrosis (IPF). <i>Journal of Thoracic Disease</i> , 2019, 11, S1740-S1754.	0.6	89
14	Low Dose Carbon Monoxide Exposure in Idiopathic Pulmonary Fibrosis Produces a CO Signature Comprised of Oxidative Phosphorylation Genes. <i>Scientific Reports</i> , 2019, 9, 14802.	1.6	12
15	Radial Endobronchial Ultrasound-guided Transbronchial Cryobiopsy. <i>Journal of Bronchology and Interventional Pulmonology</i> , 2019, 26, 245-249.	0.8	13
16	HDAC8 inhibition ameliorates pulmonary fibrosis. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2019, 316, L175-L186.	1.3	43
17	A critical role for IL-18 in transformation and maturation of naive eosinophils to pathogenic eosinophils. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 301-305.	1.5	27
18	Regulatory effects of IL-15 on allergen-induced airway obstruction. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 906-917.e6.	1.5	31

#	ARTICLE	IF	CITATIONS
19	The Antiretroviral Agent Nelfinavir Mesylate. <i>Arthritis and Rheumatology</i> , 2018, 70, 115-126.	2.9	15
20	A Phase II Clinical Trial of Low-Dose Inhaled Carbon Monoxide in Idiopathic Pulmonary Fibrosis. <i>Chest</i> , 2018, 153, 94-104.	0.4	66
21	Ethnic differences in idiopathic pulmonary fibrosis: The Japanese perspective. <i>Respiratory Investigation</i> , 2018, 56, 375-383.	0.9	22
22	Inhibition of HDAC8 Ameliorates Pulmonary Fibrosis. <i>FASEB Journal</i> , 2018, 32, lb400.	0.2	1
23	TGF- β 1 stimulates HDAC4 nucleus-to-cytoplasm translocation and NADPH oxidase 4-derived reactive oxygen species in normal human lung fibroblasts. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2017, 312, L936-L944.	1.3	19
24	Arsenic trioxide inhibits EBV reactivation and promotes cell death in EBV-positive lymphoma cells. <i>Virology Journal</i> , 2017, 14, 121.	1.4	8
25	Carcinogenic effects of oil dispersants: A KEGG pathway-based RNA-seq study of human airway epithelial cells. <i>Gene</i> , 2017, 602, 16-23.	1.0	11
26	Tubastatin ameliorates pulmonary fibrosis by targeting the TGF β 2-PI3K-Akt pathway. <i>PLoS ONE</i> , 2017, 12, e0186615.	1.1	76
27	Methylation status and AP1 elements are involved in EBV-mediated miR-155 expression in EBV positive lymphoma cells. <i>Virology</i> , 2016, 494, 158-167.	1.1	20
28	Requirement of HDAC6 for activation of Notch1 by TGF β 1. <i>Scientific Reports</i> , 2016, 6, 31086.	1.6	34
29	Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis. <i>Respiratory Research</i> , 2015, 16, 116.	1.4	114
30	Idiopathic Pulmonary Fibrosis in United States Automated Claims. Incidence, Prevalence, and Algorithm Validation. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 192, 1200-1207.	2.5	101
31	Arsenic trioxide inhibits transforming growth factor- β 1-induced fibroblast to myofibroblast differentiation in vitro and bleomycin induced lung fibrosis in vivo. <i>Respiratory Research</i> , 2014, 15, 51.	1.4	46
32	Co-treatment with arsenic trioxide and ganciclovir reduces tumor volume in a murine xenograft model of nasopharyngeal carcinoma. <i>Virology Journal</i> , 2013, 10, 152.	1.4	9
33	Overexpression of Sulf2 in idiopathic pulmonary fibrosis. <i>Glycobiology</i> , 2013, 23, 709-719.	1.3	29
34	Detecting Splicing Variants in Idiopathic Pulmonary Fibrosis from Non-Differentially Expressed Genes. <i>PLoS ONE</i> , 2013, 8, e68352.	1.1	26
35	Heparan sulfate 6-O-sulfation is dynamically regulated in idiopathic pulmonary fibrosis. <i>FASEB Journal</i> , 2012, 26, 1151.2.	0.2	0
36	An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 183, 788-824.	2.5	6,033

#	ARTICLE	IF	CITATIONS
37	Arsenic mediated disruption of promyelocytic leukemia protein nuclear bodies induces ganciclovir susceptibility in Epstein-Barr positive epithelial cells. <i>Virology</i> , 2011, 416, 86-97.	1.1	30
38	Epstein - Barr virus latent membrane protein 1 suppresses reporter activity through modulation of promyelocytic leukemia protein-nuclear bodies. <i>Virology Journal</i> , 2011, 8, 461.	1.4	3
39	The Epstein-Barr Virus Latent Membrane Protein 1 and Transforming Growth Factor- β 21 Synergistically Induce Epithelial-Mesenchymal Transition in Lung Epithelial Cells. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2011, 44, 852-862.	1.4	56
40	Current clinical trials for the treatment of idiopathic pulmonary fibrosis. <i>Respirology</i> , 2010, 15, 19-31.	1.3	24
41	Abrogation of TGF- β 21-induced fibroblast-myofibroblast differentiation by histone deacetylase inhibition. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2009, 297, L864-L870.	1.3	193
42	Requirement of HDAC6 for Transforming Growth Factor- β 21-induced Epithelial-Mesenchymal Transition. <i>Journal of Biological Chemistry</i> , 2008, 283, 21065-21073.	1.6	143
43	Treatment of Idiopathic Pulmonary Fibrosis with Etanercept. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 178, 948-955.	2.5	338
44	Engraftment of Bone Marrow Progenitor Cells in a Rat Model of Asbestos-Induced Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007, 176, 385-394.	2.5	63
45	Over-expression of PDGF-C using a lung specific promoter results in abnormal lung development. <i>Transgenic Research</i> , 2006, 15, 543-555.	1.3	22
46	Modulation of PDGF-C and PDGF-D expression during bleomycin-induced lung fibrosis. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2004, 286, L182-L188.	1.3	60
47	Pirfenidone. <i>IDrugs: the Investigational Drugs Journal</i> , 2004, 7, 166-72.	0.7	12
48	A novel murine PDGF-D splicing variant results in significant differences in peptide expression and function. <i>Biochemical and Biophysical Research Communications</i> , 2003, 308, 126-132.	1.0	9
49	Antifibrotic Therapy for the Treatment of Pulmonary Fibrosis. <i>American Journal of the Medical Sciences</i> , 2001, 322, 213-221.	0.4	47
50	Brainstem Activation of Platelet-Derived Growth Factor- β 2 Receptor Modulates the Late Phase of the Hypoxic Ventilatory Response. <i>Journal of Neurochemistry</i> , 2001, 74, 310-319.	2.1	66
51	PDGF- β 2 receptor expression and ventilatory acclimatization to hypoxia in the rat. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2000, 279, R1625-R1633.	0.9	20
52	Emphysematous Lesions, Inflammation, and Fibrosis in the Lungs of Transgenic Mice Overexpressing Platelet-Derived Growth Factor. <i>American Journal of Pathology</i> , 1999, 154, 1763-1775.	1.9	125
53	Expression of TNF and the Necessity of TNF Receptors in Bleomycin-Induced Lung Injury in Mice. <i>Experimental Lung Research</i> , 1998, 24, 721-743.	0.5	166
54	Connective tissue growth factor mRNA expression is upregulated in bleomycin-induced lung fibrosis. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 1998, 275, L365-L371.	1.3	146

#	ARTICLE	IF	CITATIONS
55	Rapid Activation of PDGF-A and -B Expression at Sites of Lung Injury in Asbestos-exposed Rats. American Journal of Respiratory Cell and Molecular Biology, 1997, 17, 129-140.	1.4	86